Harvard Bioscience working on brain, diabetes research devices
Photo | Google
Harvard Bioscience's Holliston headquarters on October Hill Road.
Via two of its subsidiaries, Holliston life-science firm Harvard Bioscience has launched two new programs aimed at studying the brain and diabetes treatment.
The launches, announced Tuesday, include subsidiaries Data Sciences International (DSI) and Multi Channel Systems (MCS).
DSI, a Minnesota-based firm acquired by Harvard in March for $70 million, has launched two telemetry implants the company hopes will meet the needs of neuroscience researches focused on large animal models. The implants are designed to acquire data from conscious, freely moving laboratory animals to provide stress-free data collection while enhancing animal welfare, the company said.
The company eyes research gains in numerous areas of study, including sleep, seizure, affective disorders, movement disorders and neurodegenerative disorders.
DSI’s related technology has already been adopted by cardiovascular researchers, said Harvard Bioscience President and CEO Jeffrey Duchemin.
“DSI is committed to providing solutions for researchers that can improve the collection of high-quality physiologic signals from unrestrained, conscious experimental animals in a low-stress environment,” Duchemin said.
MCS’ Beta Cell-System, a screening tool for diabetes research, uses multi-electrode array technology to take non-invasive measurements from small clusters of cells in the pancreas that the company hopes can support the development of new drugs to treat type 2 diabetes and for further research.
Duchemin in a statement said the system will help researchers discover new diabetes treatments and better understand the disease.
"With this product, MCS enters a new segment of the electrophysiology market,” he said.
WBJ Web Partners
Most Recent
Most Recent
0 Comments